Adam Logal
Director of Finance/CFO bij OPKO HEALTH, INC.
Vermogen: 214 997 $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Steven Rubin | M | 63 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.
eXegenics, Inc.
| 17 jaar |
Phillip Frost | M | 87 |
eXegenics, Inc.
| 17 jaar |
Athena Kartsaklis | F | 59 | 7 jaar | |
Curtis Lockshin | M | 64 | 13 jaar | |
Nell Beattie | F | 36 | 9 jaar | |
Jane Hsaio | M | 77 |
eXegenics, Inc.
| 17 jaar |
Jeff Baxter | M | 62 | 8 jaar | |
Jeffrey F. Eisenberg | M | 58 | 8 jaar | |
Allen Craig | M | - | 6 jaar | |
John Paganelli | M | 89 |
eXegenics, Inc.
| 21 jaar |
Roger Medel | M | 77 | 4 jaar | |
James Eric Callaway | M | 68 | 7 jaar | |
Nicole Anderson | F | - | 7 jaar | |
Gary Nabel | M | 70 | 2 jaar | |
Grigory G. Borisenko | M | 55 | 5 jaar | |
Michel de Wilde | M | 74 | 8 jaar | |
Alexey Vinogradov | M | 54 | 5 jaar | |
Firdaus Jal Dastoor | M | 72 | 10 jaar | |
Roger Kornberg | M | 77 | 8 jaar | |
Dmitriy Dmitrievich Genkin | M | 56 | 5 jaar | |
Richard Krasno | M | 82 | 7 jaar | |
Richard Pfenniger | M | 68 | 16 jaar | |
James F. Parslow | M | 59 | 7 jaar | |
Lin-Tsing Yu | M | 80 | 15 jaar | |
Prem Lachman | M | 64 | 3 jaar | |
Elias Zerhouni | M | 72 | 2 jaar | |
James Weisberger | M | 68 | 21 jaar | |
Stephen A. Strugnell | M | - | 10 jaar | |
Elizabeth Nabel | M | 72 | 2 jaar | |
Moshe Mizrahy | M | 71 | - | |
Steve Schaeffer | M | 73 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 15 jaar |
Francisco Diaz-Mitoma | M | 69 | 8 jaar | |
Avi Mazaltov | M | 62 | 7 jaar | |
David Anderson | M | 54 | 8 jaar | |
Oren Hershkovitz | M | 47 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 8 jaar |
Jane Pine Wood | F | 62 | 8 jaar | |
Laura Moschcovich | M | - |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 4 jaar |
Victoria Laughman | F | - | - | |
Jane Pine Wood | F | - | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Michael Scott Maguire | M | 61 | 3 jaar | |
Marc Grodman | M | 72 | 35 jaar | |
Jon Cohen | M | 69 | 3 jaar | |
Raafat E. F. Fahim | M | 70 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 9 jaar |
Robert A. Baron | M | 84 |
eXegenics, Inc.
| 14 jaar |
Warren W. Erdmann | M | - | 22 jaar | |
Richard Alan Lerner | M | 85 |
eXegenics, Inc.
| 14 jaar |
Sam Singer | M | 80 | 28 jaar | |
Subbarao V. Uppaluri | M | 75 |
eXegenics, Inc.
| 5 jaar |
Jordan I. Siegel | M | 58 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 2 jaar |
Alexis Borisy | M | 52 | 2 jaar | |
Anthony Japour | M | 64 | - | |
Scott Requadt | M | 56 | 3 jaar | |
Peter B. Davis | M | 77 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 6 jaar |
Dave A. Eichler | M | - |
eXegenics, Inc.
| - |
Michael Reich | M | 81 |
eXegenics, Inc.
| 2 jaar |
Jason Aryeh | M | 56 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 6 jaar |
Paul Kessler | M | 69 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 7 jaar |
Dmitry Yuryevich Kolosov | M | 44 | - | |
Christopher McNulty | M | 47 | 5 jaar | |
Robert S. Fishel | M | 62 | 4 jaar | |
Kate Inman | F | - | 6 jaar | |
Samuel Reich | M | 49 |
eXegenics, Inc.
| 1 jaar |
Rulfo Hernandez | M | 45 | 7 jaar | |
Joseph Benincasa | M | 74 | 10 jaar | |
Mark L. Smith | M | 72 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 7 jaar |
David J. Gury | M | 85 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 20 jaar |
John Roglieri | M | 84 | 20 jaar | |
Howard Dubinett | M | 72 | 34 jaar | |
Ben Bronstein | M | 74 | 1 jaar | |
Harry Elias | M | 93 | 11 jaar | |
Timothy Patrick Lynch | M | 54 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 5 jaar |
Pascal J. Goldschmidt | M | - | 4 jaar | |
Gili Hart | M | 49 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 13 jaar |
Jimmy Wang | M | - | 1 jaar | |
Patricia Sandler | F | 55 | - | |
Maduri Perri | F | - | 2 jaar | |
Thomas Nusbickel | M | 67 | 2 jaar | |
Gregory Henderson | M | - | - | |
Daniel Haines | M | - | 1 jaar | |
Sam Chawla | M | 49 | 4 jaar | |
Igor Gitelman | M | 48 | 11 jaar | |
Juan F. Rodriguez | M | 56 | 2 jaar | |
Geoff Monk | M | - | - | |
Scott Moomaw | M | 54 | 2 jaar | |
E. Scott Toner | M | - | 1 jaar | |
Gordon F. Martin | M | - |
eXegenics, Inc.
| - |
David Okrongly | M | - | - | |
Mitchell Steiner | M | 63 | 2 jaar | |
Ran Nussbaum | M | 51 | 1 jaar | |
S. James Freedman | M | 57 | - | |
Melvin D. Rubin | M | - | - | |
Daniel E. Greenleaf | M | 59 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 1 jaar |
Melvin L. Rubin | M | - |
eXegenics, Inc.
| - |
Ronald Trust | M | - | - | |
Christine V. Sapan | M | 76 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | - |
Ilan Kaufthal | M | 76 | - | |
Dale Pfost | M | - |
eXegenics, Inc.
| - |
Thomas E. Beier | M | 78 | - | |
Les Funtleyder | M | 55 | 2 jaar | |
Jed Fulk | M | 64 | 5 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 96 | 96.00% |
Israël | 5 | 5.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Adam Logal
- Persoonlijk netwerk